GSK plc
GSK37.150USD
-1.820-4.67%
Handelsschluss 07/31, 16:00（ET）Kurse um 15 Minuten verzögert
77.00BMarktkapitalisierung
19.35KGV TTM
mehr Informationen über GSK plc Unternehmen
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its specialty medicines prevent and treat diseases, from human immunodeficiency virus (HIV) to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from a range of diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
Unternehmensinformationen
BörsenkürzelGSK
Name des UnternehmensGSK plc
IPO-datumMay 22, 1972
Gegründet am1999
CEOMs. Deborah Waterhouse
Anzahl der mitarbeiter68629
WertpapierartOrdinary Share
GeschäftsjahresendeMay 22
Addresse980 Great West Road
StadtBRENTFORD
BörseLondon Stock Exchange
LandUnited Kingdom
PostleitzahlTW8 9GS
Telefon442080475000
Websitehttps://www.gsk.com/
BörsenkürzelGSK
IPO-datumMay 22, 1972
Gegründet am1999
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
651.54K
+0.57%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.20K
+0.09%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
36.69K
+1.00%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.74K
+1.00%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.32K
+0.84%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Mr. James Ford
Mr. James Ford
Senior Vice President, Group General Counsel, Legal and Compliance
Senior Vice President, Group General Counsel, Legal and Compliance
--
--
Ms. Sally Jackson
Ms. Sally Jackson
Senior Vice President - Global Communications and CEO Office
Senior Vice President - Global Communications and CEO Office
--
--
Dr. Tony Wood, Ph.D.
Dr. Tony Wood, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Julie Brown
Ms. Julie Brown
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
651.54K
+0.57%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
484.20K
+0.09%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
36.69K
+1.00%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
2.74K
+1.00%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
1.32K
+0.84%
Dr. Harry C. (Hal) Dietz
Dr. Harry C. (Hal) Dietz
Independent Non-Executive Director, Scientific and Medical Expert
Independent Non-Executive Director, Scientific and Medical Expert
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
US
4.72B
49.92%
Rest of world
2.54B
26.81%
Europe
2.20B
23.27%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 2
Aktualisiert: Wed, Jul 2
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Dodge & Cox
3.86%
Fidelity Management & Research Company LLC
2.48%
Fisher Investments
1.47%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
90.19%
Aktionäre
Aktionäre
Anteil
Dodge & Cox
3.86%
Fidelity Management & Research Company LLC
2.48%
Fisher Investments
1.47%
PRIMECAP Management Company
1.26%
JTC Employer Solutions Trusteee Ltd
0.74%
Other
90.19%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
9.29%
Investment Advisor/Hedge Fund
7.24%
Hedge Fund
0.83%
Research Firm
0.68%
Bank and Trust
0.10%
Individual Investor
0.06%
Insurance Company
0.06%
Pension Fund
0.05%
Family Office
0.03%
Other
81.66%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1462
376.21M
18.44%
+7.67M
2025Q1
1494
378.46M
18.50%
+5.08M
2024Q4
1481
355.06M
17.14%
+27.38M
2024Q3
1472
319.97M
15.44%
-30.07M
2024Q2
1585
322.06M
15.54%
-29.11M
2024Q1
1617
318.91M
15.39%
-23.52M
2023Q4
1614
299.81M
14.57%
-35.71M
2023Q3
1570
293.92M
14.35%
-37.46M
2023Q2
1545
286.58M
13.99%
-41.88M
2023Q1
1546
281.08M
13.72%
-55.01M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dodge & Cox
78.65M
3.85%
+10.21M
+14.92%
Mar 31, 2025
Fidelity Management & Research Company LLC
50.60M
2.48%
+6.83M
+15.61%
Mar 31, 2025
Fisher Investments
30.03M
1.47%
+11.20M
+59.43%
Mar 31, 2025
PRIMECAP Management Company
25.71M
1.26%
+446.36K
+1.77%
Mar 31, 2025
JTC Employer Solutions Trusteee Ltd
15.26M
0.75%
-5.02M
-24.75%
Mar 31, 2025
Fidelity Institutional Asset Management
9.52M
0.47%
+465.88K
+5.15%
Mar 31, 2025
Goldman Sachs Asset Management, L.P.
8.47M
0.41%
-380.46K
-4.30%
Mar 31, 2025
UBS Financial Services, Inc.
7.80M
0.38%
+1.46M
+22.95%
Mar 31, 2025
T. Rowe Price International Ltd
7.72M
0.38%
+155.40K
+2.05%
Mar 31, 2025
State Street Global Advisors (US)
6.97M
0.34%
-52.09K
-0.74%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
VanEck Pharmaceutical ETF
4.97%
The Opal International Dividend Income ETF
4.51%
Keating Active ETF
3.76%
USCF Dividend Income Fund
3.61%
Sound Equity Dividend Income ETF
3.48%
Brandes International ETF
3.35%
Altrius Global Dividend ETF
2.06%
Pacer Global Cash Cows Dividend ETF
2.01%
Fidelity Blue Chip Value ETF
1.56%
Fidelity Women's Leadership ETF
1.29%
Mehr Anzeigen
VanEck Pharmaceutical ETF
Anteil4.97%
The Opal International Dividend Income ETF
Anteil4.51%
Keating Active ETF
Anteil3.76%
USCF Dividend Income Fund
Anteil3.61%
Sound Equity Dividend Income ETF
Anteil3.48%
Brandes International ETF
Anteil3.35%
Altrius Global Dividend ETF
Anteil2.06%
Pacer Global Cash Cows Dividend ETF
Anteil2.01%
Fidelity Blue Chip Value ETF
Anteil1.56%
Fidelity Women's Leadership ETF
Anteil1.29%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
20.79B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Feb 05, 2025
GSK.NB Approximate interim Cash Dividend of gross USD 0.400652 paid on Apr 10, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Apr 10, 2025
Feb 21, 2025
Oct 30, 2024
GSK.NB Final Cash Dividend of gross USD 0.376892 paid on Jan 09, 2025 going ex on Nov 15, 2024
Nov 15, 2024
Jan 09, 2025
Nov 15, 2024
Jul 31, 2024
GSK.NB Interim Cash Dividend of gross USD 0.392813 paid on Oct 10, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Oct 10, 2024
Aug 16, 2024
May 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.384301 paid on Jul 11, 2024 going ex on May 16, 2024
May 17, 2024
Jul 11, 2024
May 16, 2024
Feb 01, 2024
GSK.NB Interim Cash Dividend of gross USD 0.404885 paid on Apr 11, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Apr 11, 2024
Feb 22, 2024
Nov 01, 2023
GSK.NB Final Cash Dividend of gross USD 0.356356 paid on Jan 11, 2024 going ex on Nov 16, 2023
Nov 17, 2023
Jan 11, 2024
Nov 16, 2023
Jul 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.343532 paid on Oct 12, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Oct 12, 2023
Aug 17, 2023
Apr 26, 2023
GSK.NB Interim Cash Dividend of gross USD 0.360944 paid on Jul 13, 2023 going ex on May 18, 2023
May 19, 2023
Jul 13, 2023
May 18, 2023
Feb 01, 2023
GSK.NB Interim Cash Dividend of gross USD 0.341883 paid on Apr 13, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Apr 13, 2023
Feb 23, 2023
Nov 02, 2022
GSK.NB Final Cash Dividend of gross USD 0.334785 paid on Jan 12, 2023 going ex on Nov 17, 2022
Nov 18, 2022
Jan 12, 2023
Nov 17, 2022
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Datum
Art
Verhältnis
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
Jun 24, 2022
Merger
5<4
